Zevra Therapeutics - ZVRA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.50
  • Forecasted Upside: 333.33%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$4.50
▼ -0.14 (-3.02%)

This chart shows the closing price for ZVRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zevra Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZVRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZVRA

Analyst Price Target is $19.50
▲ +333.33% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Zevra Therapeutics in the last 3 months. The average price target is $19.50, with a high forecast of $25.00 and a low forecast of $15.00. The average price target represents a 333.33% upside from the last price of $4.50.

This chart shows the closing price for ZVRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Zevra Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/25/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/24/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
4/2/2024Maxim GroupBoost TargetBuy$12.00 ➝ $18.00Low
4/1/2024Cantor FitzgeraldReiterated RatingOverweightLow
3/12/2024William BlairReiterated RatingOutperformLow
3/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00Low
1/12/2024Cantor FitzgeraldReiterated RatingOverweightLow
12/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $15.00Low
12/18/2023Cantor FitzgeraldReiterated RatingOverweightLow
10/6/2023Roth MkmReiterated RatingBuy ➝ Buy$25.00Low
9/1/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$20.00Low
8/15/2023Canaccord Genuity GroupBoost TargetBuy ➝ Buy$19.00 ➝ $20.00Low
3/17/2023Maxim GroupInitiated CoverageBuy$12.00Low
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/22/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/22/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/21/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/21/2023
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/20/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/19/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/20/2024
  • 8 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
4/19/2024

Current Sentiment

  • 8 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Zevra Therapeutics logo
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Read More

Today's Range

Now: $4.50
Low: $4.46
High: $4.65

50 Day Range

MA: $5.89
Low: $4.50
High: $7.08

52 Week Range

Now: $4.50
Low: $3.89
High: $7.28

Volume

261,825 shs

Average Volume

255,282 shs

Market Capitalization

$195.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81

Frequently Asked Questions

What sell-side analysts currently cover shares of Zevra Therapeutics?

The following Wall Street research analysts have issued stock ratings on Zevra Therapeutics in the last year: Canaccord Genuity Group Inc., Cantor Fitzgerald, HC Wainwright, Maxim Group, Roth Mkm, and William Blair.
View the latest analyst ratings for ZVRA.

What is the current price target for Zevra Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Zevra Therapeutics in the last year. Their average twelve-month price target is $19.50, suggesting a possible upside of 333.3%. Roth Mkm has the highest price target set, predicting ZVRA will reach $25.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $15.00 for Zevra Therapeutics in the next year.
View the latest price targets for ZVRA.

What is the current consensus analyst rating for Zevra Therapeutics?

Zevra Therapeutics currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZVRA will outperform the market and that investors should add to their positions of Zevra Therapeutics.
View the latest ratings for ZVRA.

What other companies compete with Zevra Therapeutics?

How do I contact Zevra Therapeutics' investor relations team?

Zevra Therapeutics' physical mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The company's listed phone number is (321) 939-3416 and its investor relations email address is [email protected]. The official website for Zevra Therapeutics is www.kempharm.com. Learn More about contacing Zevra Therapeutics investor relations.